Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer

Drew R Oostra,1 Erin R Macrae21Division of Hematology, Oncology, and Transplant. University of Minnesota, Minneapolis, MN, USA; 2Division of Medical Oncology, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA Abstract: Trastuzumab is a monoclonal a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oostra DR, Macrae ER
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/504b23688d244ef187efc8edad690aab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:504b23688d244ef187efc8edad690aab
record_format	dspace
spelling	oai:doaj.org-article:504b23688d244ef187efc8edad690aab2021-12-02T00:42:20ZRole of trastuzumab emtansine in the treatment of HER2-positive breast cancer1179-1314https://doaj.org/article/504b23688d244ef187efc8edad690aab2014-07-01T00:00:00Zhttp://www.dovepress.com/role-of-trastuzumab-emtansine-in-the-treatment-of-her2-positive-breast-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314 Drew R Oostra,1 Erin R Macrae21Division of Hematology, Oncology, and Transplant. University of Minnesota, Minneapolis, MN, USA; 2Division of Medical Oncology, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA Abstract: Trastuzumab is a monoclonal antibody that is used in the treatment of breast cancer. Trastuzumab targets the human epidermal growth factor receptor 2 (HER2) receptor on breast cancer cells that express this tyrosine kinase receptor. These cancers are referred to as HER2-positive breast cancer. The original studies of trastuzumab showed improved survival in metastatic breast cancer; however, resistance often develops. In the adjuvant setting, women often progress despite therapy that includes trastuzumab. Antibody–drug conjugates are a new class of powerful drugs designed to target high-dose chemotherapy directly to the cancer cells. Trastuzumab emtansine is one of these antibody–drug conjugates and was the first Food and Drug Administration approved drug for a solid tumor. Emtansine is a potent antimicrotubule agent. Trastuzumab is used to target this potent chemotherapy agent directly to the HER2-expressing cancer cells. This review article will summarize the evidence from the preclinical studies, summarize evidence from the clinical trials, discuss current clinical trials, discuss current approval of trastuzumab emtansine, and discuss future directions of research. Keywords: T-DM1, trastuzumab emtansine, Kadcyla®, breast cancer, HER2Oostra DRMacrae ERDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 103-113 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Oostra DR Macrae ER Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
description	Drew R Oostra,1 Erin R Macrae21Division of Hematology, Oncology, and Transplant. University of Minnesota, Minneapolis, MN, USA; 2Division of Medical Oncology, The James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA Abstract: Trastuzumab is a monoclonal antibody that is used in the treatment of breast cancer. Trastuzumab targets the human epidermal growth factor receptor 2 (HER2) receptor on breast cancer cells that express this tyrosine kinase receptor. These cancers are referred to as HER2-positive breast cancer. The original studies of trastuzumab showed improved survival in metastatic breast cancer; however, resistance often develops. In the adjuvant setting, women often progress despite therapy that includes trastuzumab. Antibody–drug conjugates are a new class of powerful drugs designed to target high-dose chemotherapy directly to the cancer cells. Trastuzumab emtansine is one of these antibody–drug conjugates and was the first Food and Drug Administration approved drug for a solid tumor. Emtansine is a potent antimicrotubule agent. Trastuzumab is used to target this potent chemotherapy agent directly to the HER2-expressing cancer cells. This review article will summarize the evidence from the preclinical studies, summarize evidence from the clinical trials, discuss current clinical trials, discuss current approval of trastuzumab emtansine, and discuss future directions of research. Keywords: T-DM1, trastuzumab emtansine, Kadcyla®, breast cancer, HER2
format	article
author	Oostra DR Macrae ER
author_facet	Oostra DR Macrae ER
author_sort	Oostra DR
title	Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
title_short	Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
title_full	Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
title_fullStr	Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
title_full_unstemmed	Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
title_sort	role of trastuzumab emtansine in the treatment of her2-positive breast cancer
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/504b23688d244ef187efc8edad690aab
work_keys_str_mv	AT oostradr roleoftrastuzumabemtansineinthetreatmentofher2positivebreastcancer AT macraeer roleoftrastuzumabemtansineinthetreatmentofher2positivebreastcancer
_version_	1718403494309789696

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer

Ejemplares similares